Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2015-07-567958 http://scihub22266oqcxt.onion/10.1182/blood-2015-07-567958 C4653765!4653765 !26438514     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26438514 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Blood 2015 ; 126 (21 ): 2366-9 Nephropedia Template TP {{tp|p=26438514 |t=2015. The novel mechanism of lenalidomide activity |pdf=|usr=}}{{26438514 }} gab.com Text The novel mechanism of lenalidomide activity JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=26438514 #FOAvip Lenalidomide acts by a novel drug mechanism-modulation of the substrate specificity of the CRL4(CRBN) E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4(CRBN). Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells. In del(5q) myelodysplastic syndrome, lenalidomide induces the degradation of CK1?, which preferentially affects del(5q) cells because they express this gene at haploinsufficient levels. In the future, modulation of ubiquitin ligase function may enable us to target previously "undruggable" proteins. Twit Text FOAVip The novel mechanism of lenalidomide activity ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=26438514 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26438514 #FOAvip English Wikipedia <ref>{{Cite pmid|26438514 }}</ref> The novel mechanism of lenalidomide activity #MMPMID26438514 Fink EC ; Ebert BL Blood 2015[Nov]; 126 (21 ): 2366-9 PMID26438514 show ga Lenalidomide acts by a novel drug mechanism-modulation of the substrate specificity of the CRL4(CRBN) E3 ubiquitin ligase. In multiple myeloma, lenalidomide induces the ubiquitination of IKZF1 and IKZF3 by CRL4(CRBN). Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells. In del(5q) myelodysplastic syndrome, lenalidomide induces the degradation of CK1?, which preferentially affects del(5q) cells because they express this gene at haploinsufficient levels. In the future, modulation of ubiquitin ligase function may enable us to target previously "undruggable" proteins. |Animals [MESH] |Humans [MESH] |Ikaros Transcription Factor/genetics/metabolism [MESH] |Lenalidomide [MESH] |Multiple Myeloma/*drug therapy/genetics/metabolism [MESH] |Myelodysplastic Syndromes/*drug therapy/genetics/metabolism [MESH] |Proteasome Endopeptidase Complex/metabolism [MESH] |Proteolysis/*drug effects [MESH] |Thalidomide/*analogs & derivatives/pharmacokinetics/therapeutic use [MESH]The novel mechanism of lenalidomide activity (epmc).pdf DeepDyve Pubget Overpricing